Who
Mark Schoenberg
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, UroGen Pharma.
In numbers
- Trades disclosed
- 184
- Buys
- 3
- Sells
- 41
- Bought
- $67K
- Sold
- $9.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Jan 2019
- Last trade
- 8 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $37K871 at $42.92 | filing |
| 8 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $37K871 at $42.92 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —1,667 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,667 at $0.00 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,667 at $0.00 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —1,667 | filing |
| 20 Aug 2026filed 24 Aug 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $2.9M60,677 at $47.05 | filing |
| 20 Aug 2026filed 24 Aug 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $2.9M60,677 at $47.05 | filing |
| 9 Jul 2026filed 10 Jul 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $400K10,000 at $40.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $400K10,000 at $40.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $350K10,000 at $35.01 | filing |
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $350K10,000 at $35.01 | filing |
| 8 Jun 2026filed 9 Jun 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —10,000 | filing |
| 8 Jun 2026filed 9 Jun 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $143K5,222 at $27.30 | filing |
| 8 Jun 2026filed 9 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —10,000 | filing |
| 8 Jun 2026filed 9 Jun 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $143K5,222 at $27.30 | filing |
| 8 May 2026filed 11 May 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $300K10,000 at $30.00 | filing |
| 8 May 2026filed 11 May 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $300K10,000 at $30.00 | filing |
News
Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 Shares of Stocktickerreport.com · 9 Sep 2026Analyzing Urogen Pharma (NASDAQ:URGN) and Incannex Healthcare (NASDAQ:IXHL)URGN · themarketsdaily.com · 15 Oct 2026Reviewing Cronos Group (NASDAQ:CRON) and Urogen Pharma (NASDAQ:URGN)URGN · tickerreport.com · 13 Oct 2026
1 headline in the last 90 days name Mark Schoenberg; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.